HC Wainwright Predicts Increased Earnings for FibroBiologics

FibroBiologics, Inc. (NASDAQ:FBLG) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for FibroBiologics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.44) for the year, up from their previous forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.76) EPS.

Several other research firms have also recently issued reports on FBLG. D. Boral Capital reiterated a “buy” rating and set a $16.00 target price on shares of FibroBiologics in a research report on Tuesday. Rodman & Renshaw started coverage on shares of FibroBiologics in a report on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Price Performance

NASDAQ:FBLG opened at $0.94 on Thursday. The business’s 50-day simple moving average is $1.26 and its two-hundred day simple moving average is $2.13. FibroBiologics has a 52 week low of $0.86 and a 52 week high of $13.59.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01.

Institutional Investors Weigh In On FibroBiologics

Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in FibroBiologics by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock valued at $215,000 after buying an additional 3,451 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of FibroBiologics during the 3rd quarter worth approximately $32,000. Jane Street Group LLC bought a new position in shares of FibroBiologics during the 3rd quarter valued at approximately $37,000. Intech Investment Management LLC purchased a new position in shares of FibroBiologics in the fourth quarter valued at $25,000. Finally, Virtu Financial LLC purchased a new position in shares of FibroBiologics in the fourth quarter valued at $30,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.